Outlook Therapeutics, Inc. (OTLK) Earnings History
Net Loss12 years of earnings data (2014–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Outlook Therapeutics, Inc. (OTLK) Earnings Overview
As of June 22, 2026, Outlook Therapeutics, Inc. (OTLK) reported trailing twelve-month net income of -$61M, reflecting +55.9% year-over-year growth. The company earned $-0.74 per diluted share over the past four quarters, with a net profit margin of -4416.2%.
Looking at the long-term picture, OTLK's historical earnings data spans multiple years. The company achieved its highest annual net income of -$14M in fiscal 2014.
Outlook Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including RCKT (-$209M net income), ADVM (-$204M net income, -13092.7% margin), REPL (-$315M net income), OTLK has comparable earnings metrics. Compare OTLK vs RCKT →
OTLK Earnings vs Peers
Earnings metrics vs comparable public companies
OTLK Historical Earnings Data (2014–2025)
12 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$62M | +17.2% | -$67M | $-1.79 | -4416.2% | -4744.3% |
| 2024 | -$75M | -27.8% | -$72M | $-4.06 | - | - |
| 2023 | -$59M | +10.7% | -$53M | $-4.72 | - | - |
| 2022 | -$66M | -24.2% | -$63M | $-6.23 | - | - |
| 2021 | -$53M | -50.9% | -$52M | $-6.96 | - | - |
| 2020 | -$35M | -2.1% | -$37M | $-13.47 | - | - |
| 2019 | -$35M | -14.7% | -$36M | $-39.60 | -423.8% | -445.6% |
| 2018 | -$30M | +22.5% | -$30M | $-85.00 | -974.5% | -960.0% |
| 2017 | -$39M | +27.1% | -$36M | $-288.00 | -1019.1% | -941.2% |
| 2016 | -$53M | -12.5% | -$51M | $-587.20 | -1788.7% | -1723.1% |
| 2015 | -$47M | -245.1% | -$47M | $-564.14 | -908.1% | -892.2% |
| 2014 | -$14M | - | -$12M | $-1.05 | -151.7% | -136.9% |
Download Data
Export OTLK earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
12+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
OTLK — Frequently Asked Questions
Quick answers to the most common questions about buying OTLK stock.
What is OTLK earnings per share (EPS)?
OTLK trailing twelve-month (TTM) diluted EPS is $-0.74, reflecting +55.9% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2014 to 2025 is available in the table on this page.
What is Outlook Therapeutics, Inc.'s net income?
Outlook Therapeutics, Inc. (OTLK) trailing twelve-month net income is $-61M as of 2025. Earnings grew +55.9% year-over-year.
Is OTLK profitable?
OTLK is not currently profitable on a TTM basis, reporting a net loss of $-61M. Net margin is -4416.2%. Investors should monitor for a return to profitability.
What is OTLK's earnings growth rate?
OTLK compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2014 to 2025.
What are OTLK's profit margins?
Outlook Therapeutics, Inc. net profit margin is -4416.2%, operating margin is -4744.3%, and gross margin is +46.5%. Below-average margins reflect competitive or cost pressures. Return on Equity is N/A.
Is OTLK growing earnings?
Yes, OTLK earnings are accelerating — EPS growth of +55.9% exceeds the 5-year CAGR of N/A. TTM net income reached $-61M. Earnings momentum is strengthening.
What was OTLK's best earnings year?
Outlook Therapeutics, Inc.'s highest annual net income on record is $-14M, achieved in fiscal year 2014. Earnings history on this page spans 2014 to 2025 and includes all annual and quarterly figures.
What were OTLK's earnings last quarter?
OTLK's most recent reported quarter was Q2 2026. Net income was $-4M with diluted EPS of $-0.05. For a full breakdown of all quarters, see the quarterly earnings table on this page.